반응식
[C:1]1([C@H:7]([NH:9][C:10]2[C:11]3[C:18]4[CH2:19][CH2:20][NH:21][CH2:22][C:17]=4[S:16][C:12]=3[N:13]=[CH:14][N:15]=2)[CH3:8])[CH:6]=[CH:5][CH:4]=[CH:3][CH:2]=1.Cl.[CH3:24][N:25]([CH3:32])[CH2:26]/[CH:27]=[CH:28]/[C:29](O)=[O:30]>>[CH3:24][N:25]([CH3:32])[CH2:26]/[CH:27]=[CH:28]/[C:29]([N:21]1[CH2:20][CH2:19][C:18]2[C:11]3[C:10]([NH:9][C@@H:7]([C:1]4[CH:6]=[CH:5][CH:4]=[CH:3][CH:2]=4)[CH3:8])=[N:15][CH:14]=[N:13][C:12]=3[S:16][C:17]=2[CH2:22]1)=[O:30]참가 물질
3
반응물 2
생성물 1
실험 절차
In analogy to Example 89, the title compound was prepared from N-[(1R)-1-phenylethyl]-5,6,7,8-tetrahydropyrido[4′,3′:4,5]thieno[2,3-d]pyrimidin-4-amine from Example 18A (100 mg, 0.32 mmol) and (2E)-4-(dimethylamino)but-2-enoic acid hydrochloride from Example 1A (75 mg, 0.45 mmol) to yield 23 mg (17%).
후처리
- customto yield 23 mg (17%)
출처 및 근거
- ORD 기록
- ord-0f20630317b44e9692729d04b26d6702
- 출처 데이터셋
- uspto-grants-2013_09
- 특허 번호
- US08524722B2
연결된 노트
불러오는 중…